Ready to start planning your care? Call us at 833-347-1665 to make an appointment.
James J. Harding, MD
Medical Oncologist
Titles
Assistant Attending Physician
Clinical Expertise
Gastrointestinal Cancers; Liver Cancer (Hepatocellular Carcinoma); Bile Duct Cancers (Cholangiocarcinoma); Gallbladder Cancers; Fibrolamellar Carcinoma; Early Drug Development; Immunotherapy
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
Oncology/Hematology - Memorial Sloan Kettering Cancer Center
Board Certifications
Internal Medicine; Medical Oncology
I am a board-certified medical oncologist who specializes in caring for people with liver cancer, gallbladder cancer, and bile duct cancer, as well as other gastrointestinal cancers. My primary goal is to provide the best possible treatment and individualized care for people with these diseases. I work closely with a team of surgeons, radiation oncologists, and other medical professionals who specialize in the diagnosis and treatment of gastrointestinal cancer.
Read more
In my research, I am trying to find new, effective therapies for gastrointestinal cancer, particularly primary liver and bile duct tumors. For example, I am working on ways to use a patient’s own immune system to fight cancer, which is called immunotherapy. In addition, I am investigating strategies to block specific cellular pathways that cancer uses to grow. I have developed and am leading numerous national and international clinical trials of these new cancer therapies for patients with liver, bile duct cancers, and other solid tumors.
I am also focused on improving how we conduct clinical research with patients and increasing access to clinical trials. To this aim, I am a standing member of the Institutional Review Board, which is the committee that approves all clinical research at Memorial Sloan Kettering. I am also part of several other executive committees aimed at improving the conduct of clinical trials.
My research and training has been supported by the American Society of Clinical Oncology, the National Comprehensive Cancer Network, the National Institutes of Health, the American Association for Cancer Research, and the Howard Hughes Medical Institute. My work has been published in the New England Journal of Medicine, Nature, Nature Medicine, the Journal of Clinical Oncology, Cancer Discovery, Clinical Cancer Research,and Cancer.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Visit PubMed for a full listing of Dr. Harding’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
James J. Harding discloses the following relationships and financial interests:
Bristol-Myers Squibb Provision of Services
COR2ED GmbH Provision of Services
Merck & Co Inc. Provision of Services
QED Therapeutics, Inc. Provision of Services
Research to Practice Provision of Services
Society for Immunotherapy of Cancer Provision of Services
Zymeworks Inc. Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].
